Roivant Sciences (ROIV) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.34
- Estimate
- -$0.36
- Surprise
- +4.9%
- Revenue (period 2026-06-30)
- $1.4M
- Score today
- 4.2/10
Revenue source: xbrl.
How the report landed
Roivant Sciences (ROIV) reported a narrower loss than forecast — adjusted EPS of -$0.34 against the -$0.36 estimate (a 4.9% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates ROIV Sell at 4.2/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +4.9% surprise compares with a +11.6% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Concentration risk — Pipeline: brepocitinib
- Concentration risk — Counterparty: HanAll Biopharma
- Quality below floor (1.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $34.04
- Price target
- $42.00
- Stop
- $32.01
- Upside to target
- +23.4%
- Reward-to-risk
- 3.2:1
Model outputs from TrendMatrix’s engine as of 2026-10-16 — shown for context, not personalized investment advice.
ROIV at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $24.28B
- P/E (fwd)
- -19.6
- 52-week range
- $16.88–$42.50
- Off 52-week high
- 19.9%
- RSI (14)
- 40
- Volume vs avg
- 0.64×
- Score today
- 4.2/10